"Clinical Directors Network, Inc. (CDN) is a not-for-profit practice-based research network (PBRN), and clinician training organization, founded to provide peer-initiated activities for clinicians practicing in low income, minority, and other underserved communities. CDN’s overall goal is to translate clinical research into clinical practice for the enhancement of health equity and improvement of public health."

During the past decade, Clinical Directors Network of Region II conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 1 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Clinical Directors Network of Region II" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 12 trials, followed by "Columbia University" with 4 trials sponsored, "Dartmouth-Hitchcock Medical Center" with 2 trials sponsored, "University of Rochester" with 1 trials sponsored and "Yale University" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Clinical Directors Network of Region II" #1 collaborator was "Clinical Directors Network" with 4 trials as a collaborator, "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" with 3 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator, "National Cancer Institute (NCI)" with 2 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Clinical Directors Network of Region II" are "HIV Infections" (13 trials), "Tuberculosis" (5 trials), "Breast Cancer" (2 trials), "Cervical Cancer" (2 trials) and "Colorectal Cancer" (2 trials). Many other conditions were trialed in "Clinical Directors Network of Region II" in a lesser frequency.

Most popular intervention types in "Clinical Directors Network of Region II" are "Drug" (11 trials), "Behavioral" (6 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Isoniazid" (3 trials), "Pyridoxine hydrochloride" (3 trials), "Didanosine" (2 trials), "Pyrazinamide" (2 trials) and "Rifampin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Clinical Directors Network of Region II" are 16 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Clinical Directors Network of Region II". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Clinical Directors Network of Region II, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Clinical Directors Network of Region II, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 13 trials that are defined as “Not Applicable".